Cita APA

Verstovsek, S., Besses Raebel, C., & Kiladjian, J. (2016). Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

Citación estilo Chicago

Verstovsek, Srdan, Carles Besses Raebel, y Jean-Jacques Kiladjian. Ruxolitinib Versus Best Available Therapy in Patients With Polycythemia Vera: 80-week Follow-up From the RESPONSE Trial. 2016.

Cita MLA

Verstovsek, Srdan, Carles Besses Raebel, y Jean-Jacques Kiladjian. Ruxolitinib Versus Best Available Therapy in Patients With Polycythemia Vera: 80-week Follow-up From the RESPONSE Trial. 2016.